Multigene Panel Tests Yield Clues to Breast and Ovarian Cancer Risk

GREG KENNELTY
Wednesday, August 03, 2016
Talk about this article with nurses and others in the oncology community in the General Discussions Oncology Nursing News discussion group.
Allison W. Kurian, MD, MSc

Allison W. Kurian, MD, MSc

What do patients think about being tested for many genes that may impact their hereditary risk for breast or ovarian cancer, beyond the well-known BRCA mutations? Getting a better understanding of patient attitudes toward multigene panel testing was among the goals of research recently reported at the 2016 ASCO Annual Meeting by Allison W. Kurian, MD, MSc, associate professor of Medicine and of Health Research and Policy, Stanford University School of Medicine.

In the first study she led of nearly 100,000 patients who were clinically tested for hereditary cancer risk, utilization of multigene panel sequencing was found to detect ovarian cancer–associated mutations in 11 genes.1 Using a 25-gene panel test, 14% of the 95,561 women from the database were found to have a genetic mutation. One-third of patients harbored unexpected genes—such as breast cancer genes—which do not typically appear on standard tests.

Here second study, also presented at the ASCO meeting, examined the potential harms of multiplex testing for cancer risk, such as unwarranted surgery or adverse psychological effects. However, results showed that, at a 3-month follow-up after genetic testing, the rates of patient distress, intrusive thoughts, or regret of testing were found to be low.2

In a recent interview, Kurian discussed these studies utilizing multigene panels to uncover previously undetected risks in patients with breast and ovarian cancer.

Can you give us an overview of your ongoing study on multigene panel testing?

Kurian: This is an interim report of a clinical trial that we've been doing, and that trial is evaluating a multiple-gene panel test. Instead of the older practice of testing for only one or two genes when people come in with a family history of breast cancer or colon cancer, this is a panel that tests 25 genes. This is quite a few more than we usually test.

The goals of this study are to understand the yield when we do this bigger panel and to determine what proportion of patients has harmful mutations, as well as variants of uncertain significance. We also want to very much understand the patient's perspective and the outcomes. Is this information that upsets patients? Does it drive them to do things that we would rather them not do, such as preventive surgery that might be unwarranted based on the results? Do they have high levels of distress? That's been the intention of the study.

This is an interim analysis where we've enrolled 1000 of the total 2000 patients. The study enrolled rather quickly–it was 1000 within the first year at 3 centers. One of the real strengths of the study that we see is the diversity of the patients, both in terms of ethnicity and sociodemographic background. One-third of the patients had no higher than high school as their level of education; I believe 30% to 40% were of Hispanic ethnicity, and about 29% were Spanish-speaking only. It's a nice, diverse population and one where we think we would have a good chance of really seeing the impact on a real-world population of genetic testing. This is not what we see often in a tertiary referral center, so we like that a lot.

What did you learn about patient attitudes surrounding multigene panel tests?

What we found was that about 3 months after genetic testing, which are the results we recently presented, the rates of distress, of intrusive thoughts, or regret of testing were really very low. We were encouraged that there doesn't seem to be an early signal for harm from this kind of testing from a psychological perspective. We also saw a very low use of preventive surgery among patients who had negative or uncertain results, which was encouraging to see, and we saw a good understanding of the results in terms of patients notifying their family members when a result was positive.

Those were the main findings. The caveats are that the follow-up is short at this point; it's only about 3 months follow-up. We're going to follow patients much longer, so really this is an early safety signal at this point and needs further follow-up.

Can you also talk about gene panel testing for possible ovarian cancer risks?

This is a study focused on understanding the level of cancer risk with gene mutations, again using one of these large multiple-gene panels. I think the significance here is that more and more patients are being tested with these panels, and much of the time the genes on the panels are associated with risks that are not really well-defined. For example, we might have a patient who had breast cancer and maybe we find a mutation in a gene like CHEK2 or ATM. We think we're beginning to understand the breast cancer risk, but we really don't know the associated ovarian cancer risks, and that's important because if the risk is high, this woman should be protected by being offered preventive surgery. So it would really change care.

Thus far, there have not been large, well-powered studies of penetrants for associated cancer risk with these mutations in general. What we did was use a large database from a testing laboratory to look at penetrants, or associated risk of ovarian cancer with these gene mutations. We had 95,531 total patients, so it was really a large sample size, and upward of 5000 ovarian cancer patients. That was a real strength of the study. We were able to use a few different statistical methods to analyze the risk of ovarian cancer, and we used the few different methods as sort of a backup check to make sure our results would be relatively consistent.

What we found was quite interesting. We found about 14% of ovarian cancer patients did have a genetic mutation on this panel, and about a third of these mutations were in what I would describe as unexpected genes, or genes that aren't typical for our standard testing. A number of them were genes we typically think of as breast cancer genes, not necessarily ovarian cancer genes. I think it'll be interesting to understand the ovarian cancer risk.

Caveats to this type of study is that it is a sample that is attained from clinical practice, which is not the same thing as a carefully controlled trial, so there are always questions there about data collection methods and those sorts of things. To the best of our ability, we think that these are reasonably valid based on prior work and based on what we see through different analytic methods. At this point I think this is going to be something that needs further study, but it is quite interesting in terms of the ovarian cancer risks that we see.
References
  1. Kurian AW, Hughes E, Handorf E, et al. Association of ovarian cancer (OC) risk with mutations detected by multiple-gene germline sequencing in 95,561 women. J Clin Oncol. 2016;34 (suppl; abstr 5510).
  2. Kurian AW, Idos G, Culver J, et al. Safety of multiplex gene testing for inherited cancer risk: Interim analysis of a clinical trial. J Clin Oncol. 2016;34 (suppl; abstr 1503).


Talk about this article with nurses and others in the oncology community in the General Discussions Oncology Nursing News discussion group.
External Resources

MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc
OncNurse Resources

Blogs
Continuing Education
Discussions
Web Exclusives


About Us
Advertise
Advisory Board
Careers
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2017
Intellisphere, LLC. All Rights Reserved.